我们研究了治疗前 FDG-PET 上的代谢肿瘤体积 (MTV) 和总病灶糖酵解 (TLG) 作为接受肽受体放射性核素治疗 (PRRT) 的转移性神经内分泌肿瘤 (NEN) 患者的生存预后标志物。对患者进行回顾性评价转移性 NEN 接受 PRRT 治疗。分析治疗前 FDG-PET 图像，收集的变量包括 MTV 和 TLG（按中位数分为高与低）。主要结果是通过 MTV 和 TLG（高与低）测定的总生存期 (OS) 和无进展生存期 (PFS)。纳入了 105 名患者。中位年龄为 64 岁（50% 为男性）。主要的原发 NEN 部位是小肠 (43.8%) 和胰腺 (40.0%)。中位 MTV 为 3.8 mL，中位 TLG 为 19.9。无论使用 MTV 还是 TLG，二分法都会形成相同的队列。中位 OS 为 72 个月；根据 MTV/TLG 高与低，OS 没有差异（47.4 个月与未达到；风险比，0.43；95% 置信区间 [CI]，0.18-1.04；P = 0.0594）。中位 PFS 为 30.4 个月； PFS 根据 MTV/TLG 高与低而有所不同（21.6 个月与 45.7 个月；风险比，0.35；95% CI，0.19-0.64；P = 0.007）。治疗前 FDG-PET 的低 MTV/TLG 与较长时间相关接受 PRRT 的转移性 NEN 患者的 PFS。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

We investigated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET as prognostic markers for survival in patients with metastatic neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT).A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low).One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18-1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19-0.64; P = 0.007).Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.